As you navigate your care following transplant, our free Post-Transplant Care Guidelines can help. These easy-to-understand guidelines provide a summary of the recommended tests and evaluations for your 6-month, 12-month and annual (2+ year) appointments. Knowing what to expect can help you prepare for your appointment with your doctor.
These guidelines are for allogeneic and autologous patients and are based on recommendations from experts in post-transplant care1. The guidelines are available in multiple formats to best meet your needs—explore how to access below.
Online & mobile app guidelines
- Access 6-month, 12-month and 2+ year annual checkup guidelines—anytime, anyplace
- Generate a list of tests and evaluations customized to your unique situation
- E-mail information to yourself, or your health care team
Download Mobile app:
If you prefer a printed resource, you can download or order our free Post-Transplant Care Toolkit. The toolkit includes three sets of guides: 6-month, 12-month and annual (2+ year). Each guide includes a listing of tests, along with a glossary and space for your notes.
Order Toolkit >
Your feedback matters
With your input, we can make future editions of this resource as helpful as possible for patients and caregivers. If you are interested, we will send you invitations to give feedback around the time of your 6, 12 and 24-month post-transplant doctor appointments.
Yes, I would like to provide feedback >
¹ Majhail NS, Rizzo JD, Lee SJ, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation; Center for International Blood and Marrow Transplant Research (CIBMTR), American Society for Blood and Marrow Transplantation (ASBMT), European Group for Blood and Marrow Transplantation (EBMT), Asia-Pacific Blood and Marrow Transplantation Group (APBMT), Bone Marrow Transplant Society of Australia and New Zealand (BMTSANZ), East Mediterranean Blood and Marrow Transplantation Group (EMBMT) and Sociedade Brasileira de Transplante de Medula Ossea (SBTMO). Co-published in Biol Blood Marrow Transplant. 2012; 18(3): 348-371; Bone Marrow Transplant (2012) 47, 337–341; and Hematol Oncol Stem Cel Ther 2012;5(1):1-30.
Apple, the Apple logo, iPhone, iPod touch, and iTunes are trademarks of Apple Inc., registered in the U.S. and other countries. iPad is a trademark of Apple Inc. App Store is a service mark of Apple Inc.
The Trademark BlackBerry® is owned by Research In Motion Limited and is registered in the United States and may be pending or registered in other counties. National Marrow Donor Program® is not endorsed, sponsored, affiliated with or otherwise authorized by Research in Motion Limited.
Android is a trademark of Google Inc. Use of this trademark is subject to Google Permissions.